‘Biosimilars’ for children with IBD need more research

13 julio 2015

Children with inflammatory bowel disease who are doing well on specific biological medications should not be switched to recently approved ‘biosimilar’ products, concludes an expert consensus statement of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition.img src=»http://feeds.feedburner.com/~r/sciencedaily/~4/zOrvEC2reHE» height=»1″ width=»1″ alt=»»/